Adjuvant immunotherapy for melanoma
Daniel C. Thomas, Danielle M. Bello
Abstract
Surgical resection is the treatment for early cutaneous melanoma and is often curative. Some patients, however, will subsequently relapse. High-risk features in the primary tumor and regional lymph node metastasis highlight patient subsets that are at increased risk for recurrent disease. Immunotherapy in the form of checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have been shown to improve recurrence-free survival for node-positive melanoma in the adjuvant setting and will be the focus of this review.
Topics & Concepts
MedicineIpilimumabPembrolizumabNivolumabMelanomaAdjuvantImmunotherapyOncologyInternal medicineLymph nodeAdjuvant therapyCancerCancer researchCutaneous Melanoma Detection and ManagementImmunotherapy and Immune ResponsesCAR-T cell therapy research